Phase 2 GABriella Study Represents First Step in Testing Selective Novel Y-Secretase Modulators for Prodromal Alzheimer Disease
Written by
Neurology Live
Published
0
comments
0
min
Researchers unveil promising findings from the GABriella trial, exploring a novel treatment for prodromal Alzheimer's disease at AAIC 2025.